Please check your internet connection and try again.
# Urimax (tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially binds to α1A and α1D receptors in the prostate and bladder neck, causing smooth muscle relaxation and improved urine flow.
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy for ureteral calculi (though evidence is debated regarding efficacy).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* **Maximum Dose:** 0.8 mg once daily. If no response at 0.4 mg after 2–4 weeks, the dose may be increased to 0.8 mg.
## Pediatric Dosing
* **General:** Not indicated for pediatric use.
* **Specific Uses (e.g., neurogenic bladder):** Expert opinion and institutional protocols vary significantly. Safety and efficacy are not established by the FDA. Dose by weight is generally avoided; use only under specialist supervision (urology/pediatrics).
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment indicated for mild to moderate impairment. Use caution in severe renal impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** Not recommended for patients with severe hepatic impairment (Child-Pugh grade C). No adjustment needed for moderate impairment.
## Contraindications
* Known hypersensitivity to tamsulosin or any component of the formulation.
* History of angioedema related to tamsulosin.
## Adverse Effects
* **Common:** Dizziness (orthostatic), headache, abnormal ejaculation (retrograde), rhinitis, asthenia.
* **Serious:** Orthostatic hypotension/syncope (mitigated by taking at bedtime or with food), Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, priapism (rare).
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin):** May significantly increase tamsulosin levels; avoid or reduce dose if concurrent use is necessary.
* **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Use with caution due to additive blood pressure-lowering effects; monitor for symptomatic hypotension.
* **Other Alpha-blockers:** Do not combine with other alpha-adrenergic antagonists.
## Monitoring
* Monitor blood pressure during dose initiation and escalation, particularly in patients on antihypertensive therapy.
* Assess for improvement in BPH symptom scores (e.g., AUA-SI or IPSS).
* Prior to cataract/glaucoma surgery, inform the surgeon of tamsulosin use to prevent IFIS complications.
## Clinical Pearls
* **Administration:** Must be taken on an empty stomach IF the patient cannot consistently take it after the *same* meal. Taking it after food reduces peak concentration and minimizes orthostatic side effects.
* **Capsule Integrity:** Must be swallowed whole; do not crush, chew, or open the capsule as this alters the extended-release profile.
* **Delayed Action:** Clinical benefit for BPH symptoms may take several weeks to manifest.
***
**Educational Disclaimer:** This information is for educational purposes and does not substitute for professional clinical judgment. Always verify current prescribing information, local institutional guidelines, and manufacturer package inserts before prescribing or administering medication.
